Skip to main
BNTX
BNTX logo

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 33%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech's substantial cash position of approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables provides the company with a solid financial foundation to support its ongoing research and development initiatives. The positive developments surrounding BNT323, as well as promising data from its monovalent COVID-19 vaccine, suggest potential advancements in both oncology and infectious disease areas, further strengthening its portfolio. This combination of strong financial backing and favorable pipeline progress contributes to a positive outlook for BioNTech's stock.

Bears say

BioNTech's outlook is challenged by a series of risks, including negative data from multiple candidates within its oncology pipeline and slower market uptake for its products. The company reported a net loss per diluted share of €0.12 for Q3 2025, with projections indicating a full-year loss of €3.99, signaling ongoing financial struggles. Additionally, investor focus may be diverted from BioNTech's oncology efforts due to the evolving dynamics within the COVID-19 vaccine market, influenced by regulatory changes in the U.S.

BioNTech SE (BNTX) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 33% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 12 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Nov 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $136.37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $136.37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.